Long-Term Follow-Up of Subjects Treated With AXO-AAV-GM2 for Tay-Sachs or Sandhoff Disease

Active, not recruitingOBSERVATIONAL

Enrollment

Participants

Timeline

Start Date

September 17, 2024

Primary Completion Date

December 31, 2028

Study Completion Date

December 31, 2028

Conditions

GM2 GangliosidosisTay Sachs DiseaseSandhoff Disease

Interventions

DRUG

AXO-AAV-GM2

Participants who received AXO-AAV-GM2 will be tracked in long term follow up

Trial Locations (1)

UMass Chan Medical School, Worcester

All Listed Sponsors

lead

Terence Flotte

OTHER

NCT06614569 - Long-Term Follow-Up of Subjects Treated With AXO-AAV-GM2 for Tay-Sachs or Sandhoff Disease | Biotech Hunter | Biotech Hunter